The Cannabis Hearing You're Not Allowed to Watch
Plus a November hemp cliff, a banking bill's ninth life, and a repeal campaign in a state everyone thought was settled..
The Federal Record Era Has Arrived
Cannabis stopped fighting to exist. Now it’s fighting over who controls the system once it does.
Here’s the quiet shift almost nobody is naming: cannabis reform has stopped being a protest movement and become a procedural one.
The biggest fights this week aren’t about whether cannabis should be legal. They’re about whether a federal hearing gets livestreamed. Whether reform opponents get to monopolize the official record. Whether banks can finally serve operators. Whether hemp survives a November rule. Whether a mature legal market can be repealed years after voters approved it.
That’s the real transition — from protest to procedure. And procedure is where the actual power lives.
The legalization era asked: should cannabis exist? The governance era asks something harder: who controls the system after it does? This week, that answer is being written in court filings, agency letters, banking bills, and veto fights. Here’s what happened, and what I actually think it means.
Whether you can watch the rescheduling hearing is a bigger deal than it sounds.
Marijuana Moment escalated its request to livestream the federal rescheduling hearing — taking it directly to DEA Administrator Terrance Cole after the presiding judge said he wouldn’t even consider outside filings. The hearing won’t be televised or streamed. Want to observe? Show up in person in Arlington.
This reads like a media-access squabble. It isn’t. It’s about who gets to witness the federal government build the official record on a decision that reshapes tax treatment, research, medical legitimacy, and the entire state-federal relationship.
My read: transparency isn’t a nicety here — it’s a legitimacy mechanism. We already know the DEA invited only reform opponents to formally participate. Now the one safeguard that could partially offset that imbalance — letting the public watch in real time — is being denied too. Stack those two facts together and you get a proceeding that’s hard to trust by design. Delayed transcripts aren’t the same as watching the record get built. A national decision shouldn’t hinge on who can physically fit in one room in Virginia.
The bottom line: If rescheduling is big enough to reshape national policy, it’s big enough for the public to watch. The fight over access is really a fight over legitimacy.
The opposition just showed its hand — and it’s more sophisticated than it used to be.
Reform opponents filed briefs previewing their rescheduling arguments: public health, addiction risk, impaired driving, youth exposure, alleged mental-illness links, and the claim that legalization never killed the illicit market.
None of that is surprising. What matters is the structure: the DEA is formally the proponent of moving cannabis to Schedule III, while every invited outside party opposes it. So the agency is defending reform against a room full of opponents — and that lopsided record is what courts will later review.
My read: pay attention to how the opposition has evolved. They’ve largely abandoned broad moral arguments and moved to administrative law, scientific disputes, and litigation strategy. That’s a more dangerous fight, because it plays out on technical terrain where a well-resourced minority can shape outcomes regardless of public opinion. The industry tends to celebrate that it’s “winning” — 70% public support, etc. But public opinion doesn’t get cross-examined in an administrative hearing. Evidence and procedure do. The opponents understand that. Too many operators still don’t.
The bottom line: The rescheduling fight is no longer about whether cannabis has medical value. It’s about who shapes the official federal record — and the opposition is playing that game well.
The HHC case is a test of who actually controls the hemp market.
The DEA is defending its position that HHC — a synthetic cannabinoid — is federally banned, fighting hemp companies challenging the rule in court. HHC exists in trace amounts in cannabis but is usually made commercially by chemically converting hemp-derived CBD. The DEA says that conversion makes it a controlled substance. Hemp companies say Congress legalized hemp derivatives broadly and didn’t hand the DEA authority to criminalize whole categories by interpretation.
My read: forget HHC specifically for a second. The real question this case answers is who gets to define the hemp market — Congress, the DEA, the courts, or state regulators. That’s the unresolved tension at the heart of the entire post-2018 Farm Bill economy, and it’s finally being litigated directly.
And here’s the strategic reality for operators: the hemp industry’s early advantage was the gray zone — the ambiguity that let products exist before anyone defined them. That gray zone is closing, fast, through exactly this kind of litigation and rulemaking. If you built a business on regulatory ambiguity, understand that ambiguity is a depreciating asset. The next phase belongs to whoever can operate inside clear lines, not whoever can exploit the absence of them.
The bottom line: HHC isn’t a niche cannabinoid dispute. It’s a test case for who controls the future of federally legal hemp — and the gray-market window is closing.
Massachusetts is about to test whether legalization is actually permanent.
Advocates in Massachusetts launched a campaign to defeat a ballot initiative that would roll back the state’s recreational legalization — ending regulated commercial sales while preserving possession and the medical system.
This is a genuinely important political moment, and I don’t think the industry is taking it seriously enough. Massachusetts isn’t an experimental market. It’s mature — licensed businesses, tax revenue, jobs, years of operating history. If a repeal can gain traction there, the comfortable assumption that legalization victories are permanent is wrong.
My read: this should change how operators think about political risk. Winning legalization was treated as the finish line. It’s not — defending it is now an ongoing cost of doing business. And here’s the uncomfortable part: the best defense against repeal isn’t a slick messaging campaign. It’s a market that actually works. If regulated cannabis is seen as too expensive, too corporate, too inaccessible, or too disconnected from the communities it promised to benefit, opponents will weaponize those failures. A repeal campaign succeeds or fails based on whether the public feels the legal market delivered. That’s within the industry’s control — but only if it acts like it.
The bottom line: Legalization is not politically irreversible. The strongest defense against rollback is a market that visibly works — and that’s on the industry to build.
SAFE Banking is back — and rescheduling doesn’t make it optional.
A bipartisan group refiled the SAFE Banking Act as rescheduling advances. The bill would shield banks from federal punishment for serving state-licensed cannabis businesses. It’s passed the House multiple times in prior forms. It has never become law.
That repeated failure has left much of the industry cash-heavy, underbanked, and exposed — limited credit, higher compliance costs, and real physical safety risks for employees handling cash.
My read: the critical thing readers need to understand is that rescheduling does not fix this. There’s a dangerous assumption floating around that Schedule III solves everything. It doesn’t. Schedule III could ease 280E tax pressure and improve federal recognition, but it does not automatically hand a dispensary a normal banking relationship. Those are two separate problems requiring two separate solutions.
That’s exactly why SAFE Banking remains one of the most practical reforms on the table — it targets a specific operational wound. This isn’t abstract. It’s payroll, lending, insurance, vendor payments, mortgages for industry workers, and armored-transport risk. An industry can’t professionalize while it’s financially walled off from the banking system. Don’t let the rescheduling excitement obscure how much this still matters.
The bottom line: Rescheduling isn’t legalization, and Schedule III isn’t a bank account. Cannabis can’t fully professionalize while it’s locked out of normal finance.
New Hampshire’s greenhouse veto reveals the gap between “legal” and “functional.”
New Hampshire lawmakers are pushing to override Governor Kelly Ayotte’s veto of a modest, bipartisan bill that would let medical cannabis companies grow in greenhouses — potentially cutting energy costs and lowering prices for patients.
The bill was small. It wouldn’t legalize adult-use or dramatically expand anything. It would just let treatment centers request greenhouse cultivation. The governor rejected it because she opposes expanding cultivation, full stop.
My read: that response exposes the real issue. A medical program existing on paper is not the same as a medical program that works. Programs need supply, affordability, product variety, and efficient cultivation to actually serve patients. When political leadership blocks even incremental improvements that lower costs, you get the worst outcome — legal access in theory, unaffordable or unavailable medicine in practice. And patients priced out of a regulated program don’t stop needing relief. They go without, or they go to the illicit market the program was meant to replace.
The bottom line: Medical access only means something if patients can actually afford and obtain the product. “Legal” and “functional” are not the same thing.
Virginia’s “poverty penalty” now has data behind the objection.
Virginia advocates are pushing Governor Spanberger to strip a provision raising the public-use fine from $25 to $250 — a 900% jump — from the legalization budget language. They’re calling it a “poverty penalty,” and now they have evidence: new FOIA data shows Black Virginians have been disproportionately charged for public consumption since possession was legalized in 2021.
I’ve covered this fine in past editions, but the data changes the conversation. This is no longer a hypothetical equity concern — it’s a documented enforcement pattern, and the proposed fine increase would amplify it.
My read: this is the clearest possible illustration of why legalization details matter as much as legalization itself. A state can legalize possession, build a retail market, and still preserve enforcement tools that fall unevenly on the same communities prohibition targeted. A $250 fine is a shrug for a wealthy consumer and a cascade — debt, missed rent, housing or immigration consequences — for a low-income one. If the stated goal of reform was to reduce over-policing, then quietly raising fines that land disproportionately on Black residents doesn’t just miss the goal. It inverts it.
The bottom line: Legalization is supposed to reduce punishment. If fines become the new enforcement tool — with documented racial disparities — reform loses part of its purpose.
The November hemp cliff is the year’s most consequential hemp story.
The White House is pressing Congress to stop a broad federal hemp recriminalization set to take effect in November. Under legislation signed last year, the legal definition of hemp narrows so that only products with up to 0.4mg total THC per container stay legal after November 12 — a change advocates warn could wipe out not just intoxicating products but many full-spectrum CBD products too.
My read: the most important word in this story is overcorrection. The hemp debate is no longer prohibition-versus-free-for-all. It’s regulation-versus-overcorrection, and that’s a much more nuanced fight. There’s a legitimate problem here — intoxicating hemp products sold with no age limits, testing, or labeling genuinely need rules. But a definition so broad it eliminates lawful wellness products consumers use for pain and sleep isn’t regulation. It’s accidental prohibition with a compliance deadline.
And the predictable result of overcorrection is the same every time: if compliant products vanish without a workable replacement framework, consumers don’t stop buying — they move to unregulated channels, which is the exact opposite of what the rule intends. The fact that the White House is flagging this tells you the November cliff is real. Anyone with hemp exposure should be planning for it now, not on November 11th.
The bottom line: Hemp policy is at a crossroads — Congress can build a real framework or accidentally recreate prohibition under another name. November is the deadline.
Final thought
Cannabis is no longer trying to prove it belongs in the legal economy. It’s trying to prove the legal economy can govern it fairly.
That means transparent federal hearings. Rational banking. Smart hemp rules instead of blunt bans. Medical programs that actually work for patients. Legalization that doesn’t recreate old harms through fines. And mature markets that can survive a political counterattack after the initial win.
This week showed every one of those fights happening at once — a transparency battle at the DEA, a banking bill stuck in its eternal loop, a hemp cliff months away, a repeal campaign in a state everyone assumed was settled.
The next chapter won’t be defined by slogans. It’ll be defined by structure. And the people who understand the structure first are the ones who’ll shape what comes next.
That’s what this newsletter is for.
What’s the biggest regulatory challenge your operation is facing right now? Hit reply — I read every response and it shapes what I cover next week.
If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.